Behavioral Health: Evidence-Based Engagement Drives Value

In behavioral health, it’s easy to get swept up in a good story, the slick product demo, the touching patient testimonial. But if you’re a leader evaluating an engagement program, you have to draw a hard line between a good sales pitch and a good clinical record. What I call a ‘behavioral science read’ is just doing your homework: digging into a program’s claims to see if they’re backed by actual, published behavioral science, which is the only thing that matters when you’re signing a value-based care contract.

If You Can’t Document It, You Can’t Bill For It

If a behavioral health program wants a seat at the value-based care table, you’ve got to be able to trace its results back to a specific scientific method. This record is built on empirical validation and scientific principles. With a documented foundation, claims about cost reduction and better outcomes become demonstrable facts instead of just assertions. Payers aren’t naive anymore. Their data science teams demand this kind of rigor and they will only pay for a solution that has a predictable, measurable impact on patient health and, by extension, their own costs.

ACOs Force the Issue on Evidence

Accountable Care Organizations (ACOs) are the canary in the coal mine here, because their entire business model forces them to demand documented science. Since ACOs are paid based on improving patient outcomes and cutting costs, they have to be incredibly picky about any new program they adopt. Their focus on hard numbers means a behavioral health solution won’t even get in the door of an ACO without concrete proof of its methodology and its impact. In our research, we see that getting into an ACO is a key test for any digital health company trying to fit into value-based care. If you can clearly explain your behavioral science framework and show how it works in a real ACO, you’re in a much better position to get adopted and paid.

Akili, Pear, and Omada: The Paper Trail Tells the Story

When you start digging into public records, a few names like Akili Interactive, Pear Therapeutics, and Omada Health pop up because they all have a paper trail rooted in behavioral science. Akili, for example, has extensive documentation available publicly, including through the US Food and Drug Administration (FDA) in their Akili Interactive FDA documentation. This isn’t a sales brochure. It’s the material that explains the science baked into their products. Their EndeavorRx product, a video game for treating ADHD in kids 8-12, got its first FDA clearance in June 2020, followed by a De Novo authorization and another decision in 2023, and then finally got clearance for over-the-counter use in adults in June 2024. Then there’s Pear Therapeutics. Despite having FDA-cleared prescription digital therapeutics based on solid clinical evidence Pear Therapeutics FDA clearance information, the company went out of business, filing for Chapter 11 in April 2023. The story there is a blunt reminder that regulatory clearance is just the first step. You also need a reimbursement model that actually pays for the documented science. Omada Health also has a documented behavioral science framework which you can see in their public materials like this one on their Omada Health behavioral science approach. They’re still operating, focusing on chronic disease management with programs that have been validated in a number of peer-reviewed studies. What Akili, Pear, and Omada all have in common is that they created a documented behavioral science foundation, which is what allows for a real evaluation. You have to read the record, not the marketing copy. That’s the difference between a story and a real track record.

What Payers Actually Want for Value-Based Contracts

When payers look at value-based care contracts, they’re looking past the tech for two things: demonstrable outcomes and a clear explanation of the behavioral science behind it. They need proof that an AI health platform will actually lead to AI healthcare cost reduction and make patients healthier. This means you need rigorous, peer-reviewed outcomes data, not just a few feel-good anecdotes. For a masterclass in how to do this, look at Hello Heart. Its approach to publishing outcomes evidence is exactly what’s needed for value-based care AI. Hello Heart has built a serious collection of peer-reviewed studies showing its platform’s impact on things like blood pressure control which directly lowers healthcare costs, with one example being this study on Hello Heart peer-reviewed outcomes data. By publishing verifiable data in respected journals like JAMA Network and Health Affairs, they give payers the confidence to sign on the dotted line. This focus on outcomes is everything, and Hello Heart’s financial success, raising $138 million in total funding according to Forge Global and Crunchbase, is directly tied to its ability to prove its impact.

How to Evaluate Programs Without Talking to a Sales Rep

As a leader in behavioral health, you can get a good read on a program’s real strength by looking at publicly available documents before you ever talk to a vendor. This gives you an objective view, free from the sales pitch. Your best sources are places like the US Food and Drug Administration (fda.gov), JAMA Network (jamanetwork.com), and Health Affairs (healthaffairs.org). When you search these sites, you’re looking for evidence of real behavioral science principles, clinical validation studies, and any track record with Accountable Care Organizations. Are they publishing real research, or just press releases? This document-first work helps you figure out which programs have a solid, verifiable record. It ensures your decisions are based on facts, which is the whole point of value-based care.